Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell–mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Matthias Niedermeier(The University of Texas MD Anderson Cancer Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Zachary A. Knight(Howard Hughes Medical Institute), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Antonina V. Kurtova, Kevan M. Shokat(Howard Hughes Medical Institute), William G. Wierda(University of Maryland, Baltimore), Marina Henneberg, Jianhua Hu(The University of Texas MD Anderson Cancer Center), Bryan T. Hennessy(Royal College of Surgeons in Ireland)
Cited by 143
Related Papers
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k